Product Description: Befovacimab (BAY 1093884) is a fully human monoclonal IgG2 antibody able to bind to tissue factor pathway inhibitor (TFPI). Befovacimab can be used for haemophilia A/B research[1].
Applications: Neuroscience-Neuromodulation
Formula: N/A
References: [1]Maria Elisa Mancuso, et al. Befovacimab, an anti-tissue factor pathway inhibitor antibody: Early termination of the multiple-dose, dose-escalating Phase 2 study due to thrombosis. Haemophilia. 2022 Sep;28(5):702-712. /[2]Jian-Ming Gu, et al. Mechanistic Modeling of the Pharmacodynamic and Pharmacokinetic Relationship of Tissue Factor Pathway Inhibitor-Neutralizing Antibody (BAY 1093884) in Cynomolgus Monkeys. AAPS J. 2017 Jul;19(4):1186-1195.
CAS Number: 2156634-62-5
Molecular Weight: N/A
Research Area: Cardiovascular Disease
Solubility: 10 mM in DMSO
Target: Thrombin
English
Deutsch
